Key Findings: Opioid Use and Neural Tube Defects
Main Findings from this Study
- Mothers with pregnancies affected by an NTD reported opioid use more often during the first two months of pregnancy than mothers of babies without an NTD.
- Reasons for taking opioids varied, but pain (joint or muscle pain, sprains, injury, backache, arthritis, cramps, or other unspecified pain) was the most reported reason.
- The results of this study are similar to previous studies that looked at opioid use during pregnancy and the risk of NTDs, specifically a study done by CDC using data from the National Birth Defects Prevention Study (NBDPS). This study also found that mothers who were treated with opioid medicines during the first trimester (first three months) of pregnancy were twice as likely to have a pregnancy affected by spina bifida than mothers who didn’t use opioids during the first trimester1.
About this Study
- The aim of this study was to examine if a woman’s use of opioids during the first two months of her pregnancy was linked to the risk for NTDs in her unborn baby.
- Researchers used data on babies that were due to be born between 1998 and 2010 from the Slone Epidemiology Center Birth Defects Study, an ongoing study of birth defects in the United States and Canada. The Birth Defects Study collects information on pregnancies affected by birth defects and babies born without birth defects in order to study what might cause or prevent birth defects.
- Participating U.S. and Canadian cities were Boston, Philadelphia, Toronto, and San Diego. Birth defect registries in Massachusetts and New York were also included.
- Researchers analyzed the following NTDs in this study: spina bifida, anencephaly, and encephalocele.
- Opioids that were reported in this study include codeine, oxycodone, hydrocodone, morphine, propoxyphene, meperidine, methadone, tramadol, hydromorphone, butorphanol, heroin, fentanyl, buprenorphine, nalbuphine, and diphenoxylate.
Medication Use during Pregnancy: CDC Activities
- Research: CDC funds the Centers for Birth Defects Research and Prevention, which collaborate on large studies such as theNational Birth Defects Prevention Study (births 1997-2011) and the Birth Defects Study To Evaluate Pregnancy exposureS (to start in 2014). These studies work to identify risk factors for birth defects and to answer questions about some medications taken during pregnancy.
- Technical expertise: CDC works with the U.S. Food and Drug Administration, drug manufacturers, and other professionals to help conduct studies on the effects of medication use during pregnancy and ways to prevent harmful effects.
- Collaboration: As part of the Treating for Two: Safer Medication Use in Pregnancy Initiative. CDC is committed to working with its partners, other federal agencies, and the public to build a comprehensive approach to improve the quality of data on the effects of medications used during pregnancy, translate this information into safe and effective health care for pregnant women, and make this information easily accessible to women and their healthcare providers.
Reference for Key Findings
- Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, Honein MA, National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. American Journal of Obstetrics and Gynecology. 2011;204(4):314.e1-11.